PeptiDream Inc.

Founded by Yuichi Suga (developer of Flexizyme technology and professor at the University of Tokyo) and Kichi Kubota (former chairman of the company), the company was established in Chiyoda-ku, Tokyo (the lab is located within the University of Tokyo Research Center for Advanced Science and Technology).

PeptiDream was founded in Tokyo, Japan

Obtained exclusive implementation and licensing rights with sublicensing to third parties centered on Flexizyme from the University of Tokyo.

Entered into a sub-licensable exclusive license agreement with the University of Tokyo on Flexizyme Technology

Obtained exclusive implementation and licensing rights with sublicensing to third parties for the basic patents related to Flexizyme development with the State University of New York.

Entered into a sub-licensable exclusive license agreement with the State University of New York on Flexizyme Technology

Relocated headquarters to Meguro-ku, Tokyo (within the University of Tokyo Research Center for Advanced Science and Technology).

Relocated corporate headquarters to RCAST (Research Center for Advanced Science and Technology, The University of Tokyo)

Relocated headquarters and laboratory functions to Meguro-ku, Tokyo (within the University of Tokyo Komaba Research Campus KOL).

Relocated corporate headquarters and research laboratories to Komaba Reserch Campus, The University of Tokyo

Established the proprietary technology, the Peptide Discovery Platform System (PDPS).

Established its proprietary technology “Peptide Discovery Platform System (PDPS).”

Listed on the Tokyo Stock Exchange Mothers market.

Listed on the Tokyo Stock Exchange Mothers

Changed to the First Section of the Tokyo Stock Exchange.

Listed on the first section of the Tokyo Stock Exchange.

Changed to the First Section of the Tokyo Stock Exchange.

Relocated headquarters and research institute to a new building within the international strategy base "Kings Sky Front" in Tonemachi, Kawasaki City, Kanagawa Prefecture, from Meguro-ku, Tokyo (within the University of Tokyo Komaba Research Campus KOL).

Relocated corporate headquarters to Tonomachi, Kawasaki City.

Relocated headquarters and research institute to a new building within the international strategy base "Kings Sky Front" in Tonemachi, Kawasaki City, Kanagawa Prefecture, from Meguro-ku, Tokyo (within the University of Tokyo Komaba Research Campus KOL).

Patrick Reid, who as a founding member established the PDPS core technology and oversaw various research and development programs with pharmaceutical companies as CSO (Chief Science Officer), became the president and CEO.

Founded PeptiStar Inc., a CDMO (Contract Development and Manufacturing Organization) for research, development, manufacturing, and sales of special peptide raw materials in a joint venture with Shionogi & Co., Ltd. and Sekisui Chemical Co., Ltd.

Patrick C. Reid was appointed as President and CEO

PeptiStar Inc. was founded through a joint venture agreement between PeptiDream Inc., Shionogi & Co., Ltd. and Sekisui Chemical Co., Ltd.

Founded PeptiGrowth Inc., a joint venture with Mitsubishi Corporation to develop, manufacture, and sell peptides that replace growth factors, a key component of cell culture media.

PeptiGrowth Inc. was founded through a joint venture agreement between PeptiDream Inc. and Mitsubishi Corporation.

Founded PeptiAID Inc., a joint venture with Fujitsu Ltd., Mizuho Capital Co., Ltd., Takenaka Corporation, and Kishida Chemical Co., Ltd. to develop treatments for COVID-19.

PeptiAID Inc. was founded through a joint venture agreement between PeptiDream Inc., Fujitsu Limited, Mizuho Capital Co., Ltd., Takenaka Corporation and KISHIDA CHEMICAL CO., LTD.

Made PDR Pharma Inc., a new company that succeeded the radiopharmaceutical business of Fujifilm Toyama Chemical through a spin-off, a subsidiary.

Fully acquire a newly established company, PDRadiopharma Inc. that succeeds the radiopharmaceutical business of Fujifilm Toyama Chemical.

Changed to the Prime Market of the Tokyo Stock Exchange.

Changed to the Prime Market of the Tokyo Stock Exchange